| Business Summary | | Argonaut
Technologies,
Inc.
develops
products
that
help
chemists
engaged
in
the
discovery
and
development
of
new
molecules
increase
their
productivity
and
reduce
their
operating
costs
without
compromising
the
scientific
integrity
of
their
research.
The
Company's
products
include
instruments
and
instrument
related
consumables,
and
reagents.
Argonaut
has
designed
each
of
its
instrument
products
for
a
specific
stage
of
development,
although
chemists
often
purchase
the
Company's
instruments
to
perform
chemistry
activities
in
stages
other
than
those
for
which
they
were
initially
designed.
The
Company's
reagents
are
used
by
chemists
to
perform
a
broad
range
of
chemistries
in
lead
optimization
and
pre-clinical
development
and
can
be
used
in
conjunction
with
its
instruments
or
independently. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Argonaut
Technologies
develops,
manufactures,
and
markets
products
that
enable
chemists
to
use
high
speed
parallel
synthesis
for
the
development
of
new
drugs.
The
Company's
products
include
parallel
chemical
synthesizers
and
reagents.
For
the
six
months
ended
6/30/01,
net
sales
rose
3%
to
$7.9
million.
Net
loss
rose
52%
to
$7.2
million.
Results
reflect
improvements
in
consumable
products
and
services,
offset
by
increased
stock
compensation
and
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Binkley, Ph.D., 47 Chairman,
CEO | $324K | $817K | Lissa Goldenstein, 45 Pres,
COO | 263K | 269K | Jan Hughes, 40 Sr.
VP, CTO | 189K | 203K | John Supan, 50 VP-Fin.,
CFO | -- | -- | Doug Heigel, 40 VP,
Manufacturing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|